Atea Pharmaceuticals, Inc. (AVIR) News
Follow Atea Pharmaceuticals, Inc. (AVIR) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 6 public stories across 6 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Atea Pharmaceuticals to present at Morgan Stanley global healthcare conference
Atea Pharmaceuticals (AVIR) plans to present at the Morgan Stanley 24th Annual Global Healthcare Conference.
EQUITY | Sep 08, 2026, 11:00 AM UTC
L
AVIR Reports Q2 2026 Financial Results
Atea Pharmaceuticals reports second quarter 2026 financial results and provides business update
EARNINGS | Aug 12, 2026, 08:06 PM UTC
L
AVIR - Atea Pharmaceuticals to Host Second Quarter 2026 Financial Results and Business Update Conference Call on August 12, 2026 - Click For
AVIR - Atea Pharmaceuticals to Host Second Quarter 2026 Financial Results and Business Update Conference Call on August 12, 2026
EARNINGS | Aug 05, 2026, 11:00 AM UTC
L
AVIR - Atea Pharmaceuticals Meets Both Its Primary and Secondary Endpoints in the Phase 3 C-BEYOND North America Trial Evaluating Bemnifosbu
AVIR - Atea Pharmaceuticals Meets Both Its Primary and Secondary Endpoints in the Phase 3 C-BEYOND North America Trial Evaluating Bemnifosbuvir/Ruzasvir for Hepatitis C Virus
EQUITY | Jul 28, 2026, 11:00 AM UTC
L
AVIR Atea Pharmaceuticals initiates first-in-human phase 1 clinical trial of at-587 for the treatment of hepatitis e virus
AVIR Atea Pharmaceuticals initiates first-in-human phase 1 clinical trial of at-587 for the treatment of hepatitis e virus
EQUITY | Jul 14, 2026, 11:02 AM UTC
M
AVIR Completes Enrollment
Atea Pharmaceuticals completes patient enrollment in Phase 3 C-FORWARD trial for Hepatitis C treatment
EQUITY | Jun 25, 2026, 11:00 AM UTC